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Although classified as hematopoietic cells, tissue-
resident macrophages (MFs) arise from embryonic
precursors that seed the tissues prior to birth
to generate a self-renewing population, which is
maintained independently of adult hematopoiesis.
Here we reveal the identity of these embryonic pre-
cursors using an in utero MF-depletion strategy and
fate-mapping of yolk sac (YS) and fetal liver (FL)
hematopoiesis. We show that YS MFs are the main
precursors of microglia, while most other MFs derive
from fetal monocytes (MOs). Both YS MFs and fetal
MOs arise from erythro-myeloid progenitors (EMPs)
generated in the YS. In the YS, EMPs gave rise to
MFs without monocytic intermediates, while EMP
seeding the FL upon the establishment of blood cir-
culation acquired c-Myb expression and gave rise
to fetal MOs that then seeded embryonic tissues
and differentiated into MFs. Thus, adult tissue-
resident MFs established from hematopoietic stem
cell-independent embryonic precursors arise from
two distinct developmental programs.
INTRODUCTION
Macrophages (MFs) are mononuclear phagocytes with crucial
roles in development, tissue homeostasis, and the induction of
immunity. However, they can also contribute to the pathological
processes of tumor growth and metastasis, as well as chronicinflammatory diseases including atherosclerosis and diabetes
(Lavin and Merad, 2013). There is growing interest in the clinical
manipulation of MF populations, but realizing their therapeutic
potential will require improved knowledge of their origins and
the mechanisms underlying their homeostasis.
Since the definition of the mononuclear phagocyte system
(MPS) (van Furth et al., 1972), the prevailing dogma has stated
that tissue-resident MF populations are replenished by mono-
cytes (MOs) from the blood. While this proves true for dermal
and gut MFs (Bain et al., 2014; Tamoutounour et al., 2013),
MOs do not substantially contribute to many adult tissue MF
populations either in the steady state, or even during inflamma-
tion (Hashimoto et al., 2013; Jakubzick et al., 2013; Jenkins
et al., 2011; Yona et al., 2013); rather, the majority of tissue-
resident MF populations are established during development
by embryonic precursors and maintain themselves in adults
by self-renewal (Epelman et al., 2014; Ginhoux et al., 2010;
Guilliams et al., 2013; Hoeffel et al., 2012; Schneider et al.,
2014; Schulz et al., 2012). Despite these advances in knowl-
edge, the nature and origin of the embryonic precursors of
MFs remain unknown.
Several spatially and temporally regulated waves of hemato-
poietic cells are produced in mammalian embryos, culminating
with the establishment of hematopoietic stem cells (HSCs) in
the bone marrow (BM) (Orkin and Zon, 2008; Tavian and Pe´ault,
2005). In mice, the first hematopoietic progenitors appear in the
extra-embryonic yolk sac (YS), around embryonic age 7.0 (E7.0),
where they initiate primitive hematopoiesis, producing mainly
nucleated erythrocytes and MFs (Moore and Metcalf, 1970).
From E8.25, multi-lineage erythro-myeloid progenitors (EMPs)
and lympho-myeloid progenitors (LMPs) emerge in the YS as a
‘‘second wave,’’ termed the transient definitive stage (Frame
et al., 2013; Lin et al., 2014; Palis et al., 1999). EMPs are alsoImmunity 42, 665–678, April 21, 2015 ª2015 Elsevier Inc. 665
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Figure 1. Fetal Macrophages Arise Sequentially from YS Macrophages and Fetal Monocytes
(A) Flow cytometry analysis of cells from E12.5 embryonic tissues and GIEMSA staining of purified doubletDAPICD45+CD11bloF4/80hiCD64+Ly6CYS MFs
from each tissue.
(legend continued on next page)
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found in other hemogenic tissues such as the placenta and
umbilical cord (Dzierzak and Speck, 2008) and enter the circula-
tion to colonize the fetal liver (FL) from E9.5 (Lin et al., 2014).
After E8.5, the intra-embryonic mesoderm commits to the
hematopoietic lineage and new waves of hematopoietic pro-
genitors emerge: first in the para-aortic splanchnopleura (P-Sp)
region and then in the aorta, gonads, and mesonephros (AGM)
region (Lin et al., 2014). The hematopoietic activities of the
P-Sp and AGM regions generate the pre-HSC and mature
HSC that colonize the FL around E10.5 (Kieusseian et al.,
2012; Kumaravelu et al., 2002) to finally establish definitive
hematopoiesis (Golub and Cumano, 2013; Medvinsky et al.,
2011; Orkin and Zon, 2008). The FL becomes the major hemato-
poietic organ after E11.5, generating all hematopoietic lineages
and expanding the definitive HSC population before their migra-
tion to the spleen and the BM (Christensen et al., 2004).
YS MFs first appear within the YS blood islands at E9.0 in
both mouse and rat, and develop without passing through a
monocytic intermediate stage (Takahashi et al., 1989). They
are the primary source of microglia, the resident MFs of the
central nervous system (Ginhoux et al., 2010), and also give
rise to a minor fraction of Langerhans cells (LCs), the special-
ized antigen-presenting cells of the skin (Hoeffel et al., 2012).
The major fraction of adult LCs derives from fetal MOs gener-
ated in the FL from E12.5 and recruited into fetal skin around
E14.5 (Hoeffel et al., 2012). Fetal MOs also contribute to popu-
lations of adult MFs in lung alveoli (Guilliams et al., 2013;
Schneider et al., 2014) and in the heart (Epelman et al., 2014).
Using fate-mapping to distinguish cells arising from primitive
versus definitive hematopoiesis initially suggested that adult
MF populations in lung, dermis, and spleen arise predominantly
from definitive hematopoiesis with negligible contribution from
YS MFs (Ginhoux et al., 2010). However, a new approach
exploiting the differential dependence of MFs on the transcrip-
tion factor c-Myb has since indicated that c-Myb-independent
YS MFs may be the sole origin of MFs in the lung, liver, and
pancreas, as well as of microglia and LCs (Schulz et al.,
2012). Hence, the embryonic route of origin of tissue-resident
MF populations in the adult remains controversial. Our under-
standing is further hampered by not knowing whether fetal
MOs actually arise from definitive HSC or HSC-independent
progenitors such as LMPs or EMPs.
We combined in vivo YS MF depletion with several fate-
mapping models of YS MFs and/or FL MOs to conclusively
show that YSMFs are the main precursors of microglia, whereas
most other MF populations derive from fetal MOs that seed the
tissues around E13.5. Fetal MOs in turn are revealed to derive
sequentially from HSC -independent and -dependent routes,
the former being the major pathway arising from c-Myb+ EMPs.(B) Flow cytometry analysis of cells from E14.5 and E16.5 embryos and GIEMSA st
each E14.5 tissue. (A and B) Scale bar represents 5 mM.
(C) Flow cytometry analysis of cells from E16.5 Cx3cr1+/gfp, Ccr2+/rfp, and WT
depicted (see also Figure S1A for FL analysis). Representative data from five em
(D) Kinetics of fetal MO tissue infiltration. Percentage of fetal CD11bhiF4/80lo
embryonic development (see also Figure S1B for CCR2/ data). Each dot repre
(E) MFs gated as in (A) and fetal MOs gated as in (B) within total CD11b+F4/80+
(F) Percentage of proliferative MFs gated as in (A), Ly6C+ and Ly6C MOs gate
n = 5–8) (see also Figure S2A for representative plots). Mean ± SEM from three iRESULTS
Tissue-Resident Macrophages Are Seeded Before Birth
and Proliferate In Situ
MF embryonic precursors include YS MFs and fetal MOs gener-
ated in the FL (Epelman et al., 2014; Guilliams et al., 2013; Hoeffel
et al., 2012; Schneider et al., 2014). At E10.5, YS MFs (CD45+
CD11bloF4/80hiLy6C), but not MOs, are present in the YS and
throughout the body of the embryo proper (Hoeffel et al., 2012;
Naito et al., 1990). At E12.5, YS MFs, but not MOs, were found
in liver, skin, kidney, lung, and brain rudiments (Figure 1A). How-
ever, as in the developing skin (Hoeffel et al., 2012), an influx of
fetal MOs (CD45+CD11bhiF4/80loLy6C+) was evident at E14.5
in all tissue rudiments tested (Figure 1B, blue population), except
the brain (Figures 1B–1D). Fetal MOs appear in the FL around
E12.5 (Naito et al., 1990) and exist as two populations differen-
tially expressing Ly6C, similar to adult MOs in the BM (Geiss-
mann et al., 2003). Both populations of fetal MOs also express
the chemokine receptor CCR2 (Figure 1C), though it is not
required for their emigration from the FL or recruitment into tis-
sues (Figure S1), unlike in their adult counterparts (Serbina and
Pamer, 2006). Ly6G+CCR2 granulocyte progenitors were also
detected at E14.5 (Figure S1). In contrast to adult BM MOs, fetal
MOs only began to express the chemokine receptor CX3CR1 in
the blood, following FL emigration (Figure 1C). Upon tissue infil-
tration, fetal MOs further upregulated expression of CX3CR1 and
the MF markers CD64 and MerTK, and downregulated Ly6C
(Figure 1C), suggesting their differentiation into tissue MFs. The
early tissue MF populations (Figure 1B–1E, red population)
decreased in numbers between E10.5 and E16.5, so that fetal
MOs became the major myeloid cell population in the tissues
at E16.5 (Figures 1D and 1E). The initial abundant proliferation
of both fetal MO sub-populations and MFs within the tissues
also gradually diminished with time (Figure 1F, Figure S2). By
late embryogenesis, these populations coexisted in every tissue,
without presenting any clear signs of apoptosis (Figure S2).
Thus, both YS MFs and fetal MOs contribute to tissue MF pop-
ulations present in the developing embryo.
YS Macrophages Are Not Required for Fetal
Macrophage Development
To understandwhether YSMFswere the sole progenitors ofMFs
in the adult, we asked what impact their in utero depletion would
have on the subsequent generation of tissue MFs. The colony-
stimulating factor 1 receptor (CSF-1R) is expressed on YS MFs
and fetal MOs, but only the development of the former is depen-
dent on CSF-1R (Ginhoux et al., 2010; Hoeffel et al., 2012). Thus,
we attempted to deplete YS MFs by transiently inhibiting the
CSF-1R signaling pathwaywith a blocking anti-CSF-1R antibodyaining of purified doubletDAPICD45+CD11bhiF4/80loCD64+Ly6C+MOs from
embryos. Overlay of MFs (red population) and fetal MOs (blue population) is
bryos from two litters of each strain are shown.
CD64+Ly6C+/ MOs within doubletDAPICD45+ cells on alternate days of
sents one embryo (n = 5–12).
cells (n = 5–12).
d as in (B) determined in Fucci reporter mice (see Supplemental Information,
ndependent litters is presented in (D)–(F).
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Figure 2. YS Macrophages Are Not Essential for Fetal Macrophage Development
(A–C) Pregnant females were untreated or injected with AFS98 at E6.5 and cells from embryos were analyzed by flow cytometry at E10.5 (A), E14.5 (B), and E17.5
(C). Percentages of MFs (red) and fetal MOs (blue) gated as in Figure 1 are shown. Each dot represents one embryo. Bars represent mean ± SEM (*p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001). Analysis of n = 5–12 embryos per group from 2–3 independent litters (see also Figure S2B).(clone AFS98), as recently described (Squarzoni et al., 2014).
AFS98 injection at E6.5 efficiently depleted MFs in the E10.5
YS (Figure 2A), as well as most embryonic tissue MFs from
E10.5 to E14.5 (Figure 2B, red population), but not circulating
MOs (Figure 2B, blue population). The depletion of most MFs
in AFS98-exposed embryos was transient and receded around668 Immunity 42, 665–678, April 21, 2015 ª2015 Elsevier Inc.E17.5 (Figure 2C, red population). In contrast, embryonic micro-
glia were fully depleted from E10.5 to E14.5, and only partially
repopulated at E17.5 (Figures 2A–2C), but fully repopulated
after birth (Squarzoni et al., 2014). These data suggest that
YS MFs are dispensable for generating tissue-resident MFs
in the embryo, and therefore another CSF-1R-independent
embryonic precursor can functionally replace YS MFs during
development.
Except for Microglia, Only a Minor Fraction of Tissue
Macrophages Derives from YS Macrophages
To define the relative contribution of YS MFs to the tissue MF
compartment, we used a fate-mapping mouse model express-
ing the tamoxifen-inducible Cre recombinase gene (MerCreMer)
under the control of the CSF-1R promoter (Csf1rCre/WT) (Qian
et al., 2011). We crossed the Csf1rCre/WT mice with the Cre-
reporter mouse strain Rosa26R26-EYFP/R26-EYFP (RosaEYFP) and
induced recombination in embryos by a single injection of
Hydroxytamoxifen (40OHT) into E8.5 pregnant females. Because
CSF-1R is expressed on YS MFs, which appear in the YS from
E9.0 (Ginhoux et al., 2010; Hoeffel et al., 2012), this strategy
should specifically EYFP-label YS MFs and their progeny. We
then measured the relative numbers of EYFP+ myeloid cells in
E8.5 40OHT-exposed embryos at E13.5 and E16.5, at birth,
and in adulthood (Figure 3A). At E13.5, approximately 63.2%
(±5.6) of MFs in the YS and rudiments of brain, liver, skin, kidney,
and lung were EYFP+, indicating their common YS MFs origin.
From E13.5 onward, the extent of labeling of most MFs declined,
reaching 2%–3% at birth, whereas microglia maintained a
labeling frequency above 60% throughout adulthood.
To confirm the data from the Csf1rCre/WT mice, we used a
fate-mapping model possessing a tamoxifen-inducible Cre
recombinase gene (MerCreMer) under the control of one of the
endogenous promoters of the runt-related transcription factor
1 (Runx1) locus (Samokhvalov et al., 2007). Because Runx1 is
expressed in hematopoietic progenitors, YS MF or fetal MO
progeny could be traced by injecting 40OHT at E7.5 or E8.5,
respectively (Hoeffel et al., 2012). To assess the contribution of
YS MFs to myeloid cell populations, we analyzed the frequency
of EYFP+ myeloid cells in embryos and adult mice exposed to
40OHT at E7.5 (Figure 3B). E13.5 embryos contained similar
proportions of labeled MFs in the YS (22.2%±0.9%) and brain
rudiment (23.6%±1.1%), suggesting their common origin. How-
ever, in liver, lung, skin, and kidney rudiments, significantly fewer
fetal MFs were labeled (15.5%±1.3; p = 0.002) (Figure 3B). After
this time, EYFP labeling decreased to 2%–3% by birth and into
adulthood; the same basal amounts as other leucocytes (Gin-
houx et al., 2010). These data are consistent with the minor
contribution of YS progenitors to the adult HSC pool shown pre-
viously (Samokhvalov et al., 2007). In contrast, the microglial
population maintained abundant EYFP labeling from E13.5 into
adulthood, confirming their YS MF origin (Ginhoux et al., 2010;
Hoeffel et al., 2012). Therefore, while YS MFs seed embryonic
tissues prior to the emergence of FL hematopoiesis, they do
not contribute to adult tissue MF populations, apart from micro-
glia. The absence of apoptosis within the YS MF population
in tissues (Figure S2) suggests that the decreasing relative
abundance of these cells from E13.5 likely results from dilution
by unlabeled immigrant cells.
Adult Tissue-Resident Macrophages Derive
Predominantly from Fetal Monocytes Generated
during Definitive Hematopoiesis
On the basis of our observations in the skin (Hoeffel et al., 2012),
we hypothesized that the fetal MOs infiltrating the tissuerudiments (Figure 1) were the diluting cell population. As ex-
pected, fetal MOs were not labeled in Csf1rCre/WT 3 RosaEYFP
(Csf1rCre/EYFP) embryos activated at E8.5 or in Runx1Cre/WT 3
RosaEYFP (Runx1Cre/EYFP) embryos activated at E7.5 (Figure 3C),
while injecting 40OHT into pregnant Runx1Cre/WT mice at E8.5 is
known to mark fetal MOs and their progeny (Hoeffel et al.,
2012). Exposure to 40OHT at E8.5 led to EYFP expression in
most tissue MFs in both embryos and adult mice, and not in
microglia (Figure 3D). The proportion of EYFP+ MFs and fetal
MOs from E16.5 onward was comparable, suggesting that
fetal MOs likely contribute to the EYFP signal observed in tissue
MFs (Figure 3E).
To establish whether fetal MOs directly give rise to the tissue
MFs that aremaintained into adulthood, we devised aCre-based
fate-mapping model to specifically track fetal MOs and their
progeny. Following comparative gene-expression analysis in
fetal MOs and MFs (Figure 3F and complete list in Figure S3),
and confirmation by quantitative RT-PCR (Figure 3G), we based
our model on the specific expression of S100A4 (FSP1) in fetal
MOs, because this approach has previously been successful
in fate-mapping of myeloid cells (Bhowmick et al., 2004; Hashi-
moto et al., 2013). We then crossed S100a4Cre/WT mice with
the Cre-reporter mouse strain RosaEYFP and analyzed the label-
ing of myeloid cells during development. Fetal MOs exhibited a
high labeling frequency (64.5%±6.7) (Figure 3H), whereas
E10.5 YS MFs, YS progenitors such as EMPs, and most other
leukocyteswere labeled far less frequently (17.8%±2.7) (Figure 3I
and Figure S3). Therefore, we concluded that S100a4Cre/WT mice
represent a specific fetal MO fate-mapping model, and so
proceeded to assess the labeling of tissue-resident MFs (Fig-
ure 3I). We hypothesized that MFs derived from fetal MOs should
exhibit the same extent of EYFP labeling as fetal MOs. From
E14.5 onward, the percentage of EYFP+ fetal MFs (28.4±3.6%)
was markedly greater than the percentage of EYFP+ YS MFs
and microglia (18.6±2.3%) and plateaued at the same extent
as that of the fetal MO population (64.5±6.7%; Figures 3H and
3I). This implies that fetal MFs do not arise solely from YS MFs,
and that fetal MOs are the dominant source of MFs throughout
development. Because EYFP labeling reached a plateau be-
tween E17.5 and birth, and remained stable into adulthood
(Figure S3), fetal MO-derived MFs must also be capable of
maintenance by self-renewal. This is in agreement with newborn
BM transplant experiments that showed minor post-natal con-
tribution before 12 weeks after transplantation to adult tissue-
residentMFs in the brain, epidermis, liver, kidney, and lung, while
dermal, gut, and peritoneal MFs exhibited significant donor
origin (Figure S3), likely arising from postnatal blood MO as pre-
viously published (Bain et al., 2014; Tamoutounour et al., 2013).
Of note, the relative number of EYFP+ FL MFs was relatively
greater than at other sites as early as E12.5, suggesting that
fetal MOs differentiate locally into MFs in the FL before moving
to other tissues (Figure 3I).
Fetal Monocytes Derive from HSC -Dependent
and -Independent Progenitors
We next investigated the origin of MOs generated in the FL and
observed a differentiation continuum of progenitors, as in adult
BM (Figure 4A), where MOs derive sequentially from macro-
phage-dendritic cell precursors (MDPs) and common monocyteImmunity 42, 665–678, April 21, 2015 ª2015 Elsevier Inc. 669
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Figure 3. YS Macrophages in Embryonic Tissues Are Progressively Replaced by Fetal Monocyte-Derived Macrophages
(A–E) Fate-mapping of YSMFs and fetal MOs from early development into adulthood (6 weeks old). Percentage of recombination inMFs at various time points (A),
(B), and (D) or MOs at E16.5 (C) and (E) after a single injection of 40OHT at E8.5 inCsfr1Cre/WT pregnant mice (A, C, left) (two pooled experiments, n = 5–12 for each
time point), or at E7.5 (B, C, right) (three pooled experiments, n = 8–16, for each time point), or E8.5 (D) and (E) (two pooled experiments, n = 5–16 for each time
point) in Runx1Cre/WT pregnant mice.
(F) Heatmap depicting differentially expressed genes (DEG) in fetal MOs (See Supplemental Information and Figure S3A) and representative histograms of relative
S100a4mRNA expression inMOs andMFs by gene array analysis. (G) S100a4mRNA expression determined byQ-PCR inMFs and fetal MOs (n = 3, each sample
derives from at least eight embryos or five adult mice respectively).
(H and I) Percentage of recombination in MOs at E16.5 (two pooled experiments, n = 5–10) (H), and in MFs (two pooled experiments, n = 5–10 for each time point)
(I) of S100a4Cre/eyfp embryos and adult mice (see Figures S3B and S3C for controls). Bars represent mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001).progenitors (cMoPs) (Ginhoux and Jung, 2014; Hettinger et al.,
2013).We foundLincKit+Flt3+CSF-1R+Ly6CMDP-likeprogen-
itors in the FL (FL MDP) at E12.5-16.5 (Figure 4A and Figure S4)670 Immunity 42, 665–678, April 21, 2015 ª2015 Elsevier Inc.alongside LincKit+Flt3CSF-1R+Ly6C+/ myeloid progenitors
(MPs), all of which were highly proliferative (Figure 4B) and ex-
hibited nucleolar structures typical of chromatin reorganization
(Figure 4C). The phenotype of the Ly6C+MP fraction is equivalent
to that of cMoP (Hettinger et al., 2013), whereas the Ly6C frac-
tionofMP is absent in adultBM,and thereforemight bea transient
embryonic MP population specific to the FL (Figure 4A). We thus
named them, FL cMoP and FL MP, respectively.
To clarify the relationships between these progenitors, we
isolated them from E14.5 FL and adult BM and compared their
gene-expression profiles (GEO GSE66970). Unsupervised clus-
tering analysis revealed the close proximity of each of the FL
progenitors to their BM counterparts (Figure 4D), but while fetal
MOs selectively expressed genes related to cell cycle and differ-
entiation, adult MOs exhibited an expression profile consistent
with their roles in immune responses and pathogen recognition
(Figure 4E). We also compared the gene-expression signatures
of each progenitor population by Connectivity Map (CMAP) anal-
ysis (Figure 4F and Supplemental Methods). This showed that FL
MPs and FLMDPs aremost closely related; FL cMoP thus, seem
to be an intermediate between these two populations and fetal
MOs, consistent with their higher proliferative capacity (Fig-
ure 4B) and lower expression of CCR2, CX3CR1 and Lyzozyme
(Figure S4) compared to fetal MOs. Upon culture in vitro with
CSF-1, both FL MDPs and FL MPs gave rise to MOs through a
cMoP stage (Figure S4), as seen in adult BMs (Hettinger et al.,
2013). However, the FL MP stage was not detected in FL MDP
cultures, suggesting that these two progenitors are independent
from each other. Thus, we hypothesized that two pathways of
fetal MO generation coexist in the E14.5 FL, perhaps differing
in their dependence on HSCs.
To assess the contribution of HSC to fetal MO generation, we
examined progenitors and myeloid cells at different fetal stages
in mice expressing the Cre-recombinase under the control of the
Flt3 promoter, which labels HSC progeny in adult BM (Boyer
et al., 2011). As HSC specification and maintenance are Flt3-
independent (Boyer et al., 2011; Buza-Vidas et al., 2011), few
HSC were labeled at E13.5 (2.17±0.99%) (Figure 4G), while the
FL MDP population exhibited steadily increased labeling (from
20% at E13.5, to 67% at E17.5, and 82% at birth) (Figure 4G).
Labeling of cMoP, MOs, and MFs at E17.5 was significantly
lower than of MDP and remained low throughout (Figure 4G),
suggesting a minor contribution from Flt3-dependent MDP to
fetal MOs and MFs. These data suggest that fetal MOs arise
via a Flt3-, and perhaps also HSC-, independent pathway.
To distinguish the roles of the two pathways in fetal MO gen-
eration, we investigated the lineage potential of FL progenitors.
We identified differentially expressed genes in each population
(Figure S4) and performed a Gene Set Enrichment Analysis
(GSEA) using recently published lineage-associated genes (Bo¨-
iers et al., 2013; Table S1). A significant enrichment in lymphoid
genes expression includingGata3,Rag1,Rag2, and Il7r is shown
in FL MDP (Figure S4, Table S2), similar to the E9.5 YS lympho-
myeloid progenitors (LMPs) that colonize the FL at E11.5 (Bo¨iers
et al., 2013). This might indicate some heterogeneity within
the fetal MDP population, consisting first of YS-derived LMP
during late development and then of bona fide MDP after birth,
which are related to those in adult BMs and derive from HSCs.
In contrast, FL MPs expressed erythroid- and megakaryocyte-
associated genes (Figure S4, Table S2) including as Klf1,
Gata1, and Itga2b (CD41), similar to YS erythro-myeloid pro-
genitors (EMPs), which colonize the FL around E10.0 (Frameet al., 2013): thus FL MPs might derive from EMPs. Finally, FL
cMoP and fetal MOs shared an enrichment in myeloid gene
expression, whereas lymphocyte, erythrocyte, and megakaryo-
cyte potentials were lost at the cMoP stage, consistent with their
monocytic commitment (Figure 4H and Table S2). A heatmap of
the genes that were differentially expressed in each progenitor
population, based on recently published myeloid-associated
genes and transcription factors (Friedman, 2002; Molawi and
Sieweke, 2013), highlights the distinction between fetal MDPs
and the other fetal myeloid populations (Figure S4), suggesting
a closer proximity between FL MPs, FL cMoPs, and fetal MOs
and implying that the transient FL MPs, likely the progeny of
EMPs, are the main source of fetal MOs.
c-Myb+ EMPs Colonize the Fetal Liver and Generate
Fetal Monocytes
To conclusively define the origin of fetal MOs, we returned to the
Runx1Cre/WT fate-mapping model and asked whether we could
label the ‘‘transient definitive’’ wave that generates EMPs in the
YS (Palis et al., 1999). We injected 40OHT either at E7.5, E8.5,
or E9.5 and compared the frequency of EYFP+ FL progenitors,
LinCD48c-Kit+Sca-1+CD150+ HSCs, MOs, and MFs at E13.5
(Figure 5A). Injection of 40OHT at E7.5 exclusively labeled YS
MFs in the FL, while injection at E9.5 predominantly led to label-
ing of HSCs and sequentially decreasing labeling frequencies
in FL MDPs, FL MPs, FL cMoPs, fetal MOs, and MFs. Thus,
E9.5 injection labels HSC-progeny, and reconfirms the limited
involvement of HSCs in the generation of fetal MOs and MFs,
as shown in Figure 4. 40OHT injection at E8.5 led to a high fre-
quency of EYFP+ FL MPs, FL cMoPs, fetal MOs, and MFs, but
labeled only a minor fraction of HSCs, FL MDPs (Figure 5A),
and did not label the pre-HSCs, which are generated in the
P-Sp/AGM at E9.0 before seeding the FL at E11.0 (Figure S5).
More precisely, 40OHT injection at E8.5 labels YS CD41+ EMPs
(Frame et al., 2013) en route to the FL at E10.0, and their progeny
(Figure 5B). Thus, E8.5 injection labels EMPs and their progeny.
Because YS EMPs have been implicated in the generation of
YS MFs (Kierdorf et al., 2013), while in our hands they also give
rise to fetal MOs once they seed the FL, we decided to investi-
gate their fate in these sites. As expected, EMPs arise before
YS MFs, which appear from E9.5 (Figures 5C and 5D and Fig-
ure S5), in line with their developmental relationship (Cline and
Moore, 1972; Kierdorf et al., 2013). Moreover, MFs were seen in
the absence of anymonocytic precursors before E12.5 (Figure 1),
and as described (Cline and Moore, 1972; Hoeffel et al., 2012;
Takahashi et al., 1989). In the Runx1Cre/WT model, both E7.5
and E8.5 YS EMPs gave rise locally to YS MFs able to migrate
to the FL (Figures 5E and 5F), however, E7.5-labeled EMPs re-
mained in the YS and poorly entered the blood circulation,
whereas E8.5-labeled EMPs efficiently reached the blood circu-
lation and the FL (Figure 5E, left panel). This suggests that early
EMPs differentiate locally, mainly generating YS MFs and eryth-
rocytes before the onset of blood circulation, whereas later
EMPs can reach the FL through the blood circulation, as reported
(Palis andYoder, 2001). Of note, E8.5 labeled EMPs that seed the
FL still producedMFs locally, but did not substantially contribute
to the microglial population at E13.5 (Figure 5E, right panel).
We then followed the fate of late EMPs from the YS to
the FL using the Runx1Cre/WT model, focusing on their E8.5Immunity 42, 665–678, April 21, 2015 ª2015 Elsevier Inc. 671
A B
C
D E F
G
H
(legend on next page)
672 Immunity 42, 665–678, April 21, 2015 ª2015 Elsevier Inc.
EYFP+ progeny (Figures 5F and 5G). EMPs lost the ability
to generate MFs with time. From E11.5, intermediate CD11bhi
F4/80lo CSF-1R+/ populations emerge, suggesting that EMPs
give rise to multiple myeloid progenitors, which in turn generate
granulocytes and MOs. MF populations only enlarge again at
E16.5 once the fetal MO population is established (Figure 5G).
Hence, we hypothesized that the YS Runx1+ hemogenic endo-
thelium initially gives rise to two types of EMPs: early EMPs
(labeled at E7.5), which only generate local YS MFs, and late
multipotent EMPs (labeled at E8.5) that reach the FL and differ-
entiate into multiple lineages, including MOs that ultimately
generate tissue MFs. This is supported by a previous study indi-
cating two waves of phenotypically-similar MF-committed pre-
cursors possessing distinct clonal differentiation potentials and
arising sequentially in the YS, the first at E8.0 and the second
at E8.25 (Bertrand et al., 2005).
We confirmed this hypothesis using the Csf1rCre/WT fate-map-
ping model. 40OHT injection at E8.5 in the Csf1rCre/WT model
efficiently labeled EMPs and YS MFs at E10.5 in the YS and
the FL (Figure 5H). However, increased decoupling between
the tagging frequencies of EMPs and MFs occurred with time,
suggesting that early EMPs are not maintained but are instead
rapidly replaced by later EMPs. Accordingly, in CSF-1R reporter
mice, EMPs did not express CSF-1R on their surface at E9.0
but did express it at the mRNA level (Figure S5), while from
E10.0 in the inducible Csf1rCre/WT fate-mapping model EMPs
were EYFP, explaining why neither late EMPs nor fetal MOs
were labeled. In summary, in agreement with our previous data
suggesting the presence of two distinct types of EMPs, over
time EMPs lose their ability to produce YSMFs but likely become
able to give rise to other lineages in the FL, includingMOs. As the
c-Kit+ population that contains EMPs was absent in the FL of
mice lacking c-Myb (Schulz et al., 2012), expansion and/or
differentiation of later EMPs might be regulated by c-Myb
expression, as previously suggested (Mucenski et al., 1991).
Indeed, c-Myb was expressed in EMPs, LMPs, and cMoPs in
the FL, as well as in the YS at E9.5, when EMPs ceased to give
rise to YS MFs (Figure 5I). Thus, tissue-resident MFs rely on
the generation of fetal MOs from c-Myb+ EMPs.
DISCUSSION
Here, we defined the origin and nature of the embryonic progen-
itors of major adult tissue-resident MF populations. CombiningFigure 4. Fetal Monocytes Arise from HSC-Independent and -Depende
(A) Gating strategy (from doubletDAPI cells) for myeloid progenitor identificatio
cMoP (P2, then purple gate), fetal Ly6C+ MOs (P3, then green gate) and Ly6C M
and S4B).
(B and C) Proliferative activity analyzed in Fucci-reporter mice (n = 3–6) (B) and m
progenitors (scale bar represents 5 mM; two independent experiments).
(D) Unsupervised clustering analysis of E14.5 FL and adult BM myeloid progenit
(E) Heatmap of DEG between FL and BM MOs with specific gene functionalities
(F) CMAP analysis identifies FL MDP and FL MP as early progenitors, and cM
Supplemental Information and Table S1).
(G) Percentage of recombination in Flt3Cre/mTmG embryos/mice for FL MDP, FL
lung compared to microglia (middle) and in adult MOs and adult tissue MFs (rig
experiments, *p < 0.05; **p < 0.01; ***p < 0.001).
(H) Scheme representing fetal monopoiesis based on GSEA of each FL proge
progenitors DEG in Figure S4E, Tables S2 and S3 for GSEA details and Figure Sin utero YS MF depletion and fate-mapping models revealed
that YS MFs colonize every tissue at mid-gestation, but are
dispensable for the generation of all adult tissue-resident MFs.
The exception to this was the microglial population of the central
nervous system: elsewhere YS MFs were replaced by MFs
derived from fetal MOs. By using a fate-mapping model for fetal
MOs, we showed that they colonized all embryonic tissues, apart
from the brain, and differentiated into tissue MFs able to self-
renew into adulthood. We also showed that these fetal MOs
arose mostly from YS-derived late EMPs, while YS MFs arose
from early EMPs. Thus, although arising from HSC-independent
EMPs, fetal tissue MF populations are generated via two distinct
developmental programs from two fundamentally different pre-
cursors: YS macrophages and FL monocytes.
Our results shed light on fetal monopoiesis, identifying and
characterizing the early embryonic progenitors of fetal MOs.
Fetal MOs appeared to differentiate through a process related
to adult BM monopoiesis, starting from the FL MDP or FL MP
that differentiated into FL cMOP intermediates and then Ly6C+
MOs. Two sources of fetal MOs existed: a first, HSC-indepen-
dent, wave that arose mostly from YS-derived EMPs and
accounted for the majority of fetal MOs present from E12.5–
17.5; and a second, HSC-dependent, wave that generated
a minor fraction of the fetal MO population after E17.5. In mice
expressing the Cre-recombinase under the control of the Flt3
promoter (Boyer et al., 2011), the fetal MDP population was
abundantly labeled, indicating their derivation through an Flt3-
dependent pathway. However, labeling frequency in fetal MFs
did not increase to the same amount as FL MDPs, suggesting
a minor contribution to fetal MOs and MFs from the Flt3-depen-
dent pathway. Fetal MDPs exhibited a lymphoid gene-expres-
sion signature, consistent with a contribution from LMPs to fetal
monopoiesis, though this could not be assessed in the fate-
mapping models used. Recent data from a Rag1Cre fate-
mapping model suggested that LMPs are unlikely to contribute
to adult myeloid populations (Bo¨iers et al., 2013). However, as
only 50% of LMPs express Rag1, their contribution may have
been underestimated. Whether the Flt3 lineage-tracing model
allows us to unambiguously follow fetal HSC or LMP progeny
remains to be formally established.
Primitive hematopoiesis begins within the YS blood islands
from E7.0 (Moore and Metcalf, 1970), and is characterized by
the emergence of nucleated erythrocytes, hence the denomina-
tion ‘‘primitive’’ which relates to the red cells of inferior speciesnt Pathways
n in adult BM and E14.5 FL: MDP (P1, then red gate), MP (P2, then blue gate),
Os (P3, then yellow gate) (see other time point and phenotype in Figures S4A
orphology visualized by GIEMSA staining of corresponding sorted FL myeloid
ors.
annotated.
oP as an intermediate, in generating fetal MOs (See also Figures S4C–S4E,
MP, FL cMoP, FL MOs, or FL MFs (left), in MOs and MFs in skin, kidney and
ht). Throughout the figure, bars represent mean ± SEM (n = 3–6, two pooled
nitor DEG combined with CMAP analysis (see also heatmap of FL myeloid
4D for myeloid gene heatmap).
Immunity 42, 665–678, April 21, 2015 ª2015 Elsevier Inc. 673
A B
C D
E
F G
H
I
Figure 5. c-Myb+ EMPs Colonizes the Fetal Liver and Give Rise to Monocytes
Runx1Cre/eyfp embryos activated either at E7.5, E8.5 or E9.5. Percentage of recombination in FL HSC, MDP, MP, cMoP, MOs, and MFs (two pooled litters,
n = 7–13) (A) and in YS CD41+ EMPs (B) (see also Figure S5 for gating strategy, pre-HSC, and EMP analysis).
(C) The YS from E8.5 to E12.5 embryos were analyzed by flow cytometry for presence of c-Kit+ progenitors and F4/80+ MF.
(D) E9.5 EMPs (doubletDAPICD11bF4/80c-Kit+CD41+) and YS MFs (doubletDAPICD11b+F4/80+) were sorted and visualized by GIEMSA staining.
(legend continued on next page)
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such as fish, amphibians, and birds that remain nucleated
throughout their lifespan (Palis, 2014). Such denomination was
extended toMFs in the YS due to their concomitant development
before the emergence of FL hematopoiesis. However, the notion
of primitive versus definitive has been rather ambiguous for MFs
but could now be clarified by our findings. Here, we have re-
vealed a further layer of complexity to fetal MF generation: using
our Runx1 fate-mapping system, we identified an early wave of
E7.5 Runx1+ progenitors that give rise to the EMPs, which differ-
entiate locally into YS MF, and a distinct second later wave of
E8.5 Runx1+ progenitors that give rise to the EMPs, which retain
the ability to differentiate locally into YS MFs, or migrate to
seed the FL following the establishment of blood circulation
from E9.0. The two waves of EMPs differed in their lineage po-
tency and capacity to generate MO intermediates in the FL
and YS. MFs deriving in the YS from either early or late EMPs
did not seem to go through a monocytic intermediate stage,
but rather followed a ‘‘fast-track’’ differentiation pathway, as pre-
viously described (Takahashi et al., 1989). Hence, the denomina-
tion ‘‘primitive macrophage’’ could now be used to refer to MFs
generated in the YSwithout amonocytic intermediate, andmight
even be extended to early EMPs that differentiate locally in the
YS, to distinguish them from definitive EMPs that give rise to
MO intermediates in the FL. Whether early primitive EMPs and
late definitive EMPs represent two heterogeneous progenitors
arising from independent sources or rather a single population
arising from a shared hematopoietic wave of progenitors and
exists along a continuum of maturation stages in response to
external stimuli, requires clarification. However, it is tempting
to speculate that the contrasts in differentiation potential do
not reside in the intrinsic potential given by their ontogeny, but
rather in the extrinsic signals provided by the local environment.
In fact, their multi-lineage potential is revealed upon establish-
ment of blood circulation, which allows late YS EMPs to access
the FLs where they encounter a microenvironment that permits
their development along multiple lineages at the expense of
uni-lineage MF progenitors.
Recent work by the Rodewald’s group suggested that fetal
MFs arise from HSC-independent YS EMPs (Perdiguero et al.,
2014); while we agree that EMPs arise in the YS and contribute
to most tissue-resident MFs, our data clearly demonstrate that
two waves of EMPs exist and differentially contribute to tissue
MF populations. The primitive wave gives rise mostly to local
YS MFs without monocytic intermediates, and then to microglia,
and the definitive wave gives rise to FL MOs (among other line-
ages) which subsequently differentiate into tissue MFs. Our
work emphasizes the necessary contribution of FL MOs to
most tissue-resident MFs with the exception of microglia. Of
note, in this prior study and as shown in our work, injection of(E) Runx1Cre/eyfp embryos were activated at E7.5 (upper panels) or E8.5 (lower pa
(red) at E10.5, E11.5, and E13.5 are shown (n = 5–6 from two experiments).
(F) EYFP+ EMPs from Runx1Cre/eyfp activated at E8.5 and EMP progeny were foll
granulocyte (green) generation is depicted.
(G) Quantification of MFs (red), fetal MOs (blue), and granulocytes (green) during
(H) Csf1rCre/eyfp embryos were activated at E8.5. EYFP recombination at E10.5, E
(n = 5–6 from two experiments).
(I) YS EMP, YS MF, FL myeloid progenitors, MOs, and MFs were sorted and c
mean ± SEM from triplicate samples where each sample was comprised of at l
bars represent mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001).40OHT at E8.5 or E9.5 in the inducible Csf1rCre/WT model does
not efficiently tag late EMPs and FL MOs, while efficiently label-
ing YS MFs. This is likely because early EMPs express CSF-1R
mRNA, while late EMPs do not. Such differential expression of
CSF-1R highlights the molecular heterogeneity of early versus
late EMPs. Finally, absence of long-term follow up of the tagged
cell progeny in the inducible Csf1rCre/WT model limits the capac-
ity to differentiate between the contribution of primitive versus
definitive EMPs in this later study (Perdiguero et al., 2014).
The differences in EMP lineage potential could be acquired
through expression of c-Myb, a transcription factor required for
expansion and differentiation along each of the hematopoietic
cell lineages (Ramsay and Gonda, 2008). C-Myb ablation com-
promises definitive hematopoiesis and leads to embryonic death
at E15.5 (Mucenski et al., 1991): while the earliest YS progeni-
tors, which give rise to microglia, do not express c-Myb (Kierdorf
et al., 2013), we show that EMPs arising from E8.5 do. This
agrees with previous reports indicating that primitive hematopoi-
esis can occur independently of c-Myb (Clarke et al., 2000),
whereas EMPs from definitive hematopoiesis both express and
depend upon c-Myb (Palis et al., 1999; Sumner et al., 2000;
Yoder et al., 1997). Because fetal MOs are absent in c-Myb-defi-
cient embryos (Mucenski et al., 1991; Schulz et al., 2012) and
c-Myb expression is upregulated during fetal monopoiesis, it is
likely that the change in EMP fate between the YS and the FL
is orchestrated by c-Myb. Consequently, most tissue-resident
MFs deriving from either HSC- dependent or independent fetal
MOs, rely on c-Myb activity for their generation. Earlier findings
in a different model suggested that tissue MFs derive from a
c-Myb-independent lineage via YS MFs (Schulz et al., 2012).
While embryonic YS MF numbers were unaffected by the
absence of c-Myb, far fewer c-Kit+ cells were present in the FL
ofMyb/ embryos than wild-type (Schulz et al., 2012). Because
our data suggest that EMPs express c-Myb in the YS and in the
FL, whereas E10.5 YS MFs do not, we support the notion that
late multipotent EMPs are Myb-dependent. As a result, their
contribution to tissue-resident MF populations could not be
evaluated in the Myb/ embryos (Schulz et al., 2012). It may
be that fetal MFs are unaffected in E16.5 Myb/ embryos
(Schulz et al., 2012) because they derive from c-Myb-indepen-
dent early EMPs giving rise to primitive MFs able to occupy the
empty niche left by the absence of c-Myb-dependent myeloid
cells, as a compensatory mechanism.
Microglia have a unique origin, arising from YS MFs that
maintain themselves by proliferating in situ throughout adult-
hood, and not from fetal MOs (Ginhoux et al., 2010; Kierdorf
et al., 2013). The lack of contribution from MOs to the microglial
progenitor pool could result either from a lack of intrinsic
potential or a lack of access to the developing brain. The dualnels). Recombination profile in YS, blood and FL and brain MFs (blue) or EMPs
owed in the FL during development. Primitive MFs (red), fetal MOs (blue), and
development (n = 5–12 embryos from two independent experiments).
11.5, and E12.5 in YS, blood, FL and brain MFs (blue), or EMPs (red) are shown
-Myb mRNA expression was measured by Q-PCR. Data are represented as
east eight embryos. Throughout the figure, each dot represents one embryo;
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origin of LCs suggests that the progenitor differentiation program
is not intrinsic to either YS- or FL-derived progenitors, but rather
depends on tissue-specific extrinsic factors (Hoeffel et al., 2012).
Corroborating the latter hypothesis, the blood-brain barrier is
starting to be established around E13.5 (Daneman et al., 2010),
precisely when fetal MOs colonize the tissues, thereby explain-
ing the minor influx of fetal MOs to the embryonic brain. In addi-
tion, upon depletion of YS MFs, we observed the disappearance
of microglial progenitors from E10.5 to E14.5, followed by a par-
tial repopulation at E17.5 that will be completed after birth
(Squarzoni et al., 2014), raising the question of the origin of the
repopulating cells. The nature of the repopulating cell is under
investigation, but we noted a major influx of MOs in the brain
at E14.5, a population that is not found normally. In addition,
preliminary data using our S100a4Cre/WT fate-mapping model
combined with in utero depletion of YS MFs suggest that fetal
MOs give rise to all repopulating fetal MF populations including
microglia (data not shown), excluding the possibility that tissue
MFs might formally be derived from YS MFs that escaped anti-
body depletion. This suggests that fetal MOs might give rise to
microglia if they are able to access the brain rudiment (provided
after YS MF depletion). Finally, these findings highlight the
crucial role that tissues play in shaping the MF compartment,
from the stage of controlling recruitment of MF progenitors right
through until the maturation of recruited cells into the adult MF
population.
Altogether our data provide a framework for the future investi-
gation of adult MF population heterogeneity in both regard to
their ontogeny, as well as their homeostasis at the progenitor
level. This forms a firm grounding for our understanding of
their roles in tissues in the steady state, as well as their involve-
ment in diverse pathological settings and their potential as
therapeutic targets including metabolic diseases, fibrosis, and
carcinogenesis, and opens the door to MF-targeted therapeutic
interventions.
EXPERIMENTAL PROCEDURES
Cell Suspension Preparations
Mouse ears (split into dorsal and ventral parts) or whole skin (starting from
E17.5) were first incubated for 2 hr in Hank’s balanced salt solution (HBSS)
containing Dispase (2.4 mg/ml, working activity of 1.7 U/mg; Invitrogen) to
separate dermal and epidermal sheets before subsequent collagenase
incubation. Whole tissues from adult mice, newborns or embryos were cut
into small pieces, incubated in HBSS containing 10% fetal bovine serum
and collagenase type IV (0.2 mg/ml, working activity of 770 U/mg; Sigma;
1 hr for adult tissues and newborns and 30 min for embryonic tissues)
and then passaged through a 19G needle to obtain a homogeneous cell
suspension. Embryonic blood cells were collected by decapitation in
PBS 10 mM EDTA and red blood cells were lysed. When embryos were
harvested prior to E13.5, the different tissues were isolated under a binocular
microscope (Leica M320). For fetal liver cell suspensions, the whole liver was
isolated and passed through a 19G needle without collagenase treatment.
Analysis was carried out by flow cytometry, gating on singlets of DAPI–
(4,6-diamidino-2-phenylindole) CD45+ cells.
Induction of Cell Tagging with 4-Hydroxytamoxifen
For fate-mapping experiments, Runx1MerCreMer/WT 3 RosaR26R-EYFP/R26R-EYFP
mice were used as described (Samokhvalov et al., 2007). Briefly, 4-hydroxyta-
moxifen (40OHT) (Sigma) was prepared as previously reported and adminis-
tered by intraperitoneal injection (3–5 mg) to pregnant mice at 7.0–10.0 days
post-conception (dpc). Day of embryonic development was estimated by676 Immunity 42, 665–678, April 21, 2015 ª2015 Elsevier Inc.taking the day of vaginal plug observation as 0.5 dpc. As 40OHT treatment dur-
ing pregnancy interferes with normal delivery, to trace cells marked during
embryogenesis into adulthood, caesarean sections were carried out at term
and neonates were fostered by lactating females. Active recombination in
these genetically targeted mice occurs in a narrow time frame that does not
exceed 24 hr post-injection and leads to irreversible expression of the
enhanced yellow fluorescent protein (EYFP) in Runx1+ cells and their progeny
(Samokhvalov et al., 2007). Similar procedures were followed for the use of
Csf1rMerCreMer/WT mice.
Flow Cytometry
Flow cytometric studies were performed using a BDFACSCanto and aBD LSR
II (BD Biosciences) with subsequent data analysis using FlowJo software
(Tree Star). Fluorochrome- or biotin- conjugated monoclonal antibodies
(mAbs) (see Supplemental Experimental Procedures), the corresponding iso-
type-matched controls, and secondary reagents were purchased either from
BD Biosciences or eBioscience. Annexin-V staining was performed using
the Annexin kit (BD PharMingen) according to the manufacturer’s protocol.
Yolk Sac Macrophage Depletion
Pregnant C57BL/6 females were treated with anti–CSF-1R mAb (aCSF-1R,
clone AFS98) or the rat IgG2a isotype control (clone R35-95; BD Biosciences)
at E6.5 by intraperitoneal injection (3 mg, in sterile PBS). aCSF-1R mAb was
purified from culture supernatant of AFS98 hybridoma (Sudo et al., 1995),
grown in a CELLine Flask (BD) in serum-free medium (PFHM-II; Invitrogen).
In Vivo Proliferation Assay
Proliferation of monocyte and macrophage populations was investigated us-
ing the fluorescent ubiquitination-based cell-cycle indicator (Fucci) transgenic
mouse model in which the green-emitting fluorescent protein Azami Green is
fused to Geminin, a ubiquitination oscillator whose expression is regulated
by cell-cycle-dependent proteolysis, resulting in the expression of fluores-
cence in cells in S/G2/M phases (Sakaue-Sawano et al., 2008) and their iden-
tification by flow cytometry.
Statistical Analysis
Repeated-measures ANOVA, Mann-Whitney tests, and unpaired t tests (with
a 95% confidence) were performed using Prism 6.0 (GraphPad Software).
All p-values are two-tailed. *p < 0.05; **p < 0.01; and ***p < 0.001.
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